Future directions
During the PROstart 2002 global workshop, an international multidisciplinary consensus was successfully reached on three aspects of treating early prostate cancer: treating localized disease, treating locally advanced disease, and the value of patient -doctor dialog during treatment. The consensus views on these topics are summarized in Table 1 .
A recurring theme in the consensus views is the importance of determining the patient's needs and expectations; this is necessary, since the goals of managing the disease may vary greatly from one patient to another. In addition, successful disease management may not mean the same thing to the patient as it does to the doctor. To understand the patient's needs, expectations and goals, it is essential that there is a good relationship between the patient and doctor. This can be facilitated by providing the patient with complete, unbiased, comprehensive information at all stages of care, on the disease itself, the treatment options available, and the adverse effects associated with each option. A team-based approach to disease management should be used, and the patient should be encouraged to take an active part in choosing a treatment option.
The need to consider the patient's wishes is particularly highlighted in the consensus views for treating localized disease. These patients are faced with a large range of treatment options, principally involving curative intent. Depending on the patient's goals, the deciding factor in treatment choice may be the likelihood of cure or the adverse effects associated with each treatment option. The potential to be cured may be less for patients with locally advanced disease, and the consensus views on this topic concentrate on recommending treatment options that are thought most likely to prevent or reduce disease Treating localized disease After discussing all options and reviewing all available information, sufficient time should be allowed for the patient to make a decision on his treatment Discussion of treatment options (curative vs conservative) should include the patient's partner and other clinicians The final decision on treatment rests with the patient, but the clinician should make recommendations if asked to do so, taking into account the priorities of the patient and the information available from randomized clinical trials
Treating locally advanced disease
Hormone therapy is a recommended component of disease management and may improve survival Radiotherapy should be combined with neoadjuvant and/or adjuvant hormone therapy
Patient -doctor dialog There should be an individualized approach to care There is time to come to a decision in early prostate cancer The patient should have access to honest, balanced and comprehensive information The opportunity should be provided for the patient to involve his partner throughout if he wishes Communication skills are of the utmost importance for health professionals dealing with prostate cancer; education should be provided The media and patient support groups have an important role to play in improving public knowledge Prostate Cancer and Prostatic Diseases (2002) 5, Suppl 2, S15-S16 ß 2002 Nature Publishing Group All rights reserved 1365-7852/02 $25.00 www.nature.com/pcan progression. The choice of treatment option should be based on the risk factors associated with the tumor (eg prostate-specific antigen level and Gleason score), but should also take into account the patient's wishes.
Reaching a global consensus is the first major step towards developing best practice guidelines for the treatment of early prostate cancer. The next step is to introduce the consensus views into individual countries; initially, this may require adaptations to the consensus views to allow for geographical variations in treatment practices and healthcare teams. National discussion groups were formed at the PROstart meeting to specifically address how to implement the consensus views within each country. The outcomes of these discussions will be available on the PROstart website (www.prostartonline.com) later this year. In addition, a third PROstart global workshop will be held in 2003.
Prostate cancer is a challenging disease to treat, particularly in the early stages. It is hoped that the development and implementation, through the PROstart initiative, of the consensus views will go some way towards globally uniting those involved in the care of patients with prostate cancer. It is hoped that this will eventually lead to the creation of best practice guidelines in the treatment of early disease.
